Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Ono Pharma |
---|---|
Information provided by: | Ono Pharma |
ClinicalTrials.gov Identifier: | NCT00083421 |
The purpose of this study is to establish the presence of an effect of treatment with ONO-2506PO in patients with Alzheimer's Disease, based upon cognitive and global scales.
Condition | Intervention | Phase |
---|---|---|
Alzheimer's Disease |
Drug: ONO-2506PO |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Effects of ONO-2506PO in Patients With Alzheimer's Disease |
Ages Eligible for Study: | 50 Years to 90 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | ONO-2506POU010 |
Study First Received: | May 24, 2004 |
Last Updated: | November 9, 2007 |
ClinicalTrials.gov Identifier: | NCT00083421 |
Health Authority: | United States: Food and Drug Administration; Canada: Therapeutic Products Division |
Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Alzheimer Disease Central Nervous System Diseases Neurodegenerative Diseases |
Brain Diseases Dementia Cognition Disorders Delirium |
Nervous System Diseases Tauopathies |